16 Minutes #59: The U.S. Vaccine Rollout

    Today on our news analysis show 16 Minutes — since this show is all about teasing apart what’s hype/ what’s real and where we are on the long arc of innovation — we’re taking a quick pulse-check with the experts on just where we are with the COVID vaccine rollout in the U.S. 

    Our experts today are Dr. Bob Wachter, the Chair of the Department of Medicine at UCSF — he has come to additional prominence during the pandemic as a regular public resource, providing daily updates & reports on Twitter throughout the crisis. He’s also currently guest-hosting the “In the Bubble” podcast. We also have Dr. Vineeta Agarwala, a general partner in a16z bio who is also a practicing clinician at Stanford Hospital. 

    You can catch our ongoing coverage of all things vaccines at a16z.com/vaccines.

    But in this episode we cover where we really are right now with the vaccine rollout — is it working or not, given all the buzz and mixed messages we’ve been hearing on social and in the media? We cover everything from distribution, in practice (that is, from the clinical/ on-the-ground perspective); to other dynamics (such as new strains), to demand for the vaccines (including vaccine hesitancy, and it’s not just about anti-vaxxers); to the data (which is where we start). On Friday the CDC reported that about 77 million people in the U.S. have currently received at least one dose of a COVID vaccine, with about 42 million who have been fully vaccinated. 


    The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

    This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

    Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

    Biology is eating the world

    Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.